BioTrack Capital
ActiveVenture Capital
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at BioTrack Capital.
Key people at BioTrack Capital.
BioTrack Capital is a China-based venture capital firm specializing in healthcare and life sciences investments. Founded around 2016-2017, it focuses on building and incubating innovative companies primarily in biopharma, biotechnology, medical devices, and wellness sectors. The firm typically invests in later-stage startups (around 4-5 years old) with deal sizes ranging from $10 million to $50 million, often participating alongside other prominent investors such as Vision Plus Capital and Fosun Group. BioTrack Capital plays a significant role in the Chinese startup ecosystem by fueling growth in cutting-edge healthcare ventures and supporting their scale-up through multiple funding rounds[1][2][3].
BioTrack Capital was founded in 2016 or 2017 in Shanghai, China, by key partners including Feng Tao (Founding Partner), Kevin Chen (CEO and Founding Partner), and Lisa Lei (Partner). The firm evolved with a clear focus on life sciences and healthcare technology, aligning its investment strategy with China's growing emphasis on biotech innovation. Over time, BioTrack Capital has expanded its portfolio to include over 50 investments mainly in China, with some presence in the U.S. and Singapore, reflecting its strategic positioning in the Asian healthcare venture capital landscape[1][2][3].
BioTrack Capital rides the global trend of increasing investment in healthcare innovation, particularly in China’s rapidly expanding biotech and medical technology sectors. The timing is favorable due to China's strategic national initiatives to boost domestic biotech capabilities and the growing demand for advanced medical solutions. Market forces such as aging populations, rising healthcare spending, and government support for innovation create a fertile environment for BioTrack Capital’s investments. The firm influences the broader ecosystem by enabling startups to scale, fostering collaboration among investors, and contributing to the maturation of China’s life science industry[1][2][3].
Looking ahead, BioTrack Capital is likely to continue expanding its portfolio in high-potential healthcare subsectors, possibly increasing cross-border investments as Chinese biotech firms seek global partnerships. Trends such as precision medicine, digital health, and advanced therapeutics will shape its investment focus. The firm’s influence may grow as it leverages its network and expertise to help startups overcome regulatory hurdles and commercialize innovations. BioTrack Capital’s role as a key enabler of China’s healthcare innovation ecosystem positions it well for sustained impact in the coming years[1][2][3].
Key people at BioTrack Capital.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jan 30, 2026 | Spurious | $35.0M Seed | Highlight Capital | Hankang Capital, InnoPinnacle Fund, Lichen Capital, LongRiver Investments |
| Jan 1, 2021 | SeekGene | $15.0M Series A | — | — |
| Jun 1, 2020 | CF PharmTech | $51.0M Series F | — | — |
